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Abstract Validating prognostic or predictive candidate
genes in appropriately powered breast cancer cohorts are of
utmost interest. Our aim was to develop an online tool to
draw survival plots, which can be used to assess the rele-
vance of the expression levels of various genes on the
clinical outcome both in untreated and treated breast cancer
patients. A background database was established using
gene expression data and survival information of 1,809
patients downloaded from GEO (Affymetrix HGU133A
and HGU133?2 microarrays). The median relapse free
survival is 6.43 years, 968/1,231 patients are estrogen-
receptor (ER) positive, and 190/1,369 are lymph-node
positive. After quality control and normalization only
probes present on both Affymetrix platforms were retained
(n = 22,277). In order to analyze the prognostic value of a
particular gene, the cohorts are divided into two groups
according to the median (or upper/lower quartile) expres-
sion of the gene. The two groups can be compared in terms
of relapse free survival, overall survival, and distant
metastasis free survival. A survival curve is displayed, and
the hazard ratio with 95% confidence intervals and logrank
P value are calculated and displayed. Additionally, three
subgroups of patients can be assessed: systematically
untreated patients, endocrine-treated ER positive patients,
and patients with a distribution of clinical characteristics
representative of those seen in general clinical practice in
the US. Web address: www.kmplot.com. We used this
integrative data analysis tool to confirm the prognostic
power of the proliferation-related genes TOP2A and
TOP2B, MKI67, CCND2, CCND3, CCNDE2, as well as
CDKN1A, and TK2. We also validated the capability of
microarrays to determine estrogen receptor status in 1,231
patients. The tool is highly valuable for the preliminary
assessment of biomarkers, especially for research groups
with limited bioinformatic resources.
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Background
Biomarkers are a readily measurable set of parameters with
directly applicable information on the clinical course of
cancer. The first biomarkers were established at the cellu-
lar, histological, or whole organism level. For example,
tumor grade has traditionally been regarded as an important
indicator of breast cancer prognosis [1]. Also, Adjuvant!
Online, a SEER (Surveillance Epidemiology and End
Results—an authoritative source of information on cancer
incidence and survival in the United States) data-based
algorithm, integrates various clinical (age, nodal status)
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and histopathological parameters (estrogen receptor, size,
grade) to predict 10-year mortality rate in breast cancer
[2, 3]. With the introduction of biomarkers such as estrogen
receptor and HER2 in evaluating the clinical course of
breast cancer, biomarker discovery has shifted toward a
more molecular level with a large number of individual
gene or protein expression levels being tested. To date
numerous additional genes have been suggested as being
capable to predict prognosis in breast cancer [4]. This shift
has also been further investigated by the fact that qualita-
tive biomarkers are usually difficult to assess in a consis-
tent fashion; e.g., the concordance of tumor grade
assessments by three independent pathologists is less than
50% [5].
Following the identification of new gene expression-
based biomarkers various steps of independent validations
must be completed. While direct measurement of gene
expression levels, e.g., by QRT–PCR, is the most reliable
method to do this; it is often desirable to test few candidate
genes without major further investment in order to choose
the most promising candidates and eliminate those that are
most likely to fail. Microarray cohorts combined with
appropriate clinical data offer exactly such a cost effective
tool to prescreen potential new biomarkers.
The accuracy of microarray-based gene expression
measurements has been evaluated by a wide array of
diverse studies [6–8], leading to the general conclusion that
it is a powerful surveyor of gene expression changes when
its limitations are considered properly. While absolute gene
expression levels are hard to estimate, relative gene
expression levels can be measured in a consistent fashion;
therefore, a preliminary test to evaluate prognostic bio-
markers based on their relative gene expression levels is a
prudent exploitation of already existing clinical microarray
cohorts.
The Kaplan–Meier estimator (also known as the product
limit estimator) estimates the survival function from life-
time data. An important benefit of the Kaplan–Meier curve
is that the method takes into account ‘‘censored’’ data—
losses from the cohort before the final outcome is observed
(for instance, if a patient withdraws from a study). When
no truncation or censoring occurs, the Kaplan–Meier curve
is equivalent to the empirical distribution [9]. The associ-
ation between a clinical parameter (or biomarker) and
survival can be visualized by drawing a Kaplan–Meier plot
in which patients are split into groups according to the
parameter.
Our aim was to use the data generated in gene expres-
sion studies to develop an online survival analysis tool that
can be used to assess the effect of single genes on breast
cancer prognosis. Since many of the current ASCO pro-
posed proliferation-related genes [10] do not hold sufficient
evidence to be introduced in clinical practice, we also
aimed to assess the effect of their expression on survival.
Finally, we evaluated the capability of microarray data to
predict estrogen receptor (ER) status.
Methods
A database was established using gene expression data
downloaded from GEO. For this, the keywords ‘‘breast’’,
‘‘cancer’’, ‘‘gpl96’’, and ‘‘gpl570’’ were used in GEO (http://
www.ncbi.nlm.nih.gov/geo/). Only publications with
available raw data, clinical survival information, and at least
30 patients were included. Only Affymetrix HG-U133A
(GPL96) and HG-U133 Plus 2.0 (GPL570) microarrays
were considered, because they are frequently used and
because these two particular arrays have 22,277 probe sets in
common. The use of nearly identical platforms is important
since different platforms for gene-expression profiling
measure expression of the same gene with varying precision,
on different relative scales, and with different dynamic
ranges [11]. An overview of the clinical data is presented on
Table 1.
After an initial quality control, redundant samples
(n = 384) were excluded [12]. The raw CEL files were
MAS5 normalized in the R statistical environment (www.
r-project.org) using the affy Bioconductor library [13].
MAS5 can be applied to individual chips, making future
extensions of the database uncomplicated. Moreover, MAS5
ranked among the best normalization methods when com-
pared to the results of RT-PCR measurements in our recent
study [8]. Then, only probes measured on both GPL96 and
GPL570 were retained (n = 22,277). At this stage, we
performed a second scaling normalization to set the average
expression on each chip to 1,000 to avoid batch effects [14].
The Kaplan–Meier plotter is set up using a central server
which can be reached over the internet. The background
database is handled by a MySQL server, which integrates
gene expression and clinical data simultaneously. Data is
loaded into the R statistical environment, where calcula-
tions are performed. The package ‘‘survival’’ is used to
calculate and plot Kaplan–Meier survival curves, and the
number-at-risk is indicated below the main plot. Hazard
ratio (and 95% confidence intervals) and logrank P are
calculated and displayed. The user receives the feedback
over the webpage. The system is summarized on Fig. 1.
In order to determine expression of the ER gene ESR1,
we used the results from Gong et al. [15], who found that
the probe set 205225_at had the highest mean and median
expression values, the greatest range of expression values,
and the strongest correlation with clinical ER status, and
was therefore suggested for future ESR1 determinations.
We also used their suggested threshold of 500 to determine
ER status of the samples.
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When comparing data from Surveillance, Epidemiology,
and End Results (SEER), the population-based tumor reg-
istry program of the National Cancer Institute [16] to the
overall characteristics of the patients used in our analysis
(only patients with all available clinical data), some dif-
ferences were observed. These differences could influence
actual results when interpreting the resulting Kaplan–Meier
plot. Therefore, a randomization algorithm-selected set of
patients of similar, over-represented clinical characteristics
were removed in making an additional filter for the
analysis.
Results
We identified 1,809 unique patients meeting our criteria in
GEO. The median relapse free survival is 6.43 years, 968/
1,231 patients are estrogen-receptor positive by histologi-
cal or radioimmunoassay based evaluation, and 190/1,369
are lymph-node positive. Furthermore, 1,593 patients have
relapsed free survival data, 594 have overall survival data
and 767 have distant metastasis free survival data.
In order to analyze the association between a queried gene
and survival, the samples are grouped according to the
median (or upper or lower quartile) expression of the
selected gene, and then the two groups are compared by a
Kaplan–Meier plot. Before running the analysis, the patients
can be filtered using ER status, lymph node status, and/or
grade. Additionally, as an alternative to relapse free sur-
vival, overall survival and distant metastasis free survival
can be employed. The web address is www.kmplot.com.
Many of the published microarray cohorts used patient
selection criteria corresponding to the goals of the partic-
ular study. Therefore, the patients in our database may not
be representative of breast cancer patients in general. Users
of our service may be interested how a given gene is
associated with outcome in a general ‘‘all comer’’ cohort,
as might be seen in the everyday clinical practice. For this
we established a patient cohort similar to SEER published
prevalences. The eliminated samples were ER positive,
node negative patients in all three grades from different
datasets. The resulting reduced database includes 500
patients, and the prevalences of the individual breast cancer
subtypes and clinical parameters are similar to the actual
US prevalence numbers (Table 2).
A clinician might be interested in a specific clinical
question related to the treatment of the patients. Therefore,
we established two options for additional filtering: the first
cohort represents a truly prognostic setting (e.g., systemi-
cally untreated patients, n = 809) and the second cohort
the endocrine-treated ER positive patients (n = 414).
The ER status as determined by IHC was available for
1,231 patients, which we used to assess the efficacy of ERT
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determination on the microarray. The ER-positive samples
(n = 968) had a markedly higher expression of the ESR1
gene than did the ER negative samples (n = 263). On
Fig. 2, we illustrate the distribution of ER positive and ER
negative samples as measured by microarray and IHC.
90.2% of the ER positive (945 out of 1,048), and 89.8% of
ER negative (160 out of 183) predictions were correct.
Markers of cell proliferation have been proposed and
evaluated as prognostic factors in breast cancer. We com-
puted Kaplan–Meier plots for the markers Ki67, cyclin D,
cyclin E, the cyclin inhibitors p27 and p21, thymidine
kinase, and topoisomerase II to assess their effect on
prognosis (Table 3; Fig. 3).
Table 2 Overall clinical characteristics of the patients in our data-
base, and the subset designed to match US prevalences are compared
to SEER reported US prevalences
Alla Prevalence-matched subset SEER
n % n % %
ER? 774 87.8 412 82.4 76.3
ER- 108 12.2 88 17.6 23.7
Node? 176 20.0 168 33.6 36.5
Node- 706 80.0 332 66.4 63.5
Grade 1 166 18.8 86 17.2 17.1
Grade 2 469 53.2 219 43.8 44.0
Grade 3 247 28.0 195 39.0 38.9
Total n 882 500
a Only samples for which all clinical data was available
simultaneously
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Fig. 2 Box plot showing normalized expression of ESR1 (probe set
205225_at) in 1,231 tumors divided into two groups based on the IHC
diagnosis of ER (1 = ER positive, n = 968; 0 = ER negative,
n = 263)
Query
http://www.kmplot.com
Raw CEL files
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Combining platforms and 
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Clinical 
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GEO
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data
Fig. 1 Flowchart of the
Kaplan–Meier plotter
728 Breast Cancer Res Treat (2010) 123:725–731
123
Discussion
The discovery of prognostic markers is a high priority task
in breast cancer biomarker research. In our study, we
combined raw data from several studies; this enabled us to
treat the data as a single dataset which makes the use of
existing algorithms directly applicable. By combining
multiple datasets the statistical power is dramatically
increased. Prior to our study, no suitable tool was available
which could help to estimate the prognostic value of any
selected gene in a large cohort of clinical patients. In our
service, after dividing the patients into two groups based on
the expression of the selected gene, a Kaplan–Meier plot is
generated. In this, 1,809 patient are used all together, of
which 1,593 have relapse free survival data, 594 have
overall survival data, and 767 have distant metastasis free
survival data. As our service performs the requested anal-
ysis in real time on the original data, the extension of the
analysis (e.g., the inclusion of additional samples or fil-
tering for other clinical parameters) will be easily feasible
in the future.
Since gene expression arrays might be used to confirm
ER status, we implemented an estimation of ER status
based on gene expression data. Previous studies have
shown significant correlation between mRNA concentra-
tions and routinely established (IHC based) clinical ER
status [17–19]. In the study of Gong et al. [15] the same
platform was used as in our study. They used immuno-
histochemistry to independently measure the ER status and
to establish a statistical threshold for ESR1 mRNA level to
assign ER status to tumor samples. They suggested using
an ESR1 mRNA cutoff value of 500 to identify ER positive
status with an overall accuracy of 90%. By using the above
threshold in the 1,231 patients with available ER status
data, we also achieved overall accuracy of 90%. Thus, we
confirmed the capability to use microarrays to measure ER
status. Because we performed a second scaling normali-
zation, the original MAS5 expression values (as used in the
study of Gong et al.) were slightly transformed. However,
this transformation made it possible to compare gene
expression measurements made on two different micro-
array platforms. On our webpage, the ER status for all
Table 3 The association between proliferation genes and relapse-free survival
Marker Gene name Affymetrix ID HR RFS p
MKI67 Antigen identified by monoclonal antibody Ki-67 212020_s_at 0.95 (0.82–1.1) 1
212021_s_at 1.13 (0.97–1.31) 1
212022_s_at 1.8 (1.5–2.1) 1.14E-12
212023_s_at 1.3 (1.1–1.5) 0.0352
CCND1 Cyclin D1 208711_s_at 1.3 (1.1–1.5) 0.0374
208712_at 1.07 (0.93–1.25) 1a
CCND2 Cyclin D2 200951_s_at 1.2 (1.0–1.4) 0.946
200952_s_at 0.62 (0.53–0.72) 1.23E-08
200953_s_at 0.68 (0.58–0.79) 9.02E-06
CCND3 Cyclin D3 201700_at 0.7 (0.6–0.82) 0.000114
CCNE1 Cyclin E1 213523_at 1.2 (1.1–1.4) 0.1518
CCNE2 Cyclin E2 205034_at 2.5 (2.1–2.9) \1e-16
211814_s_at 1.2 (1.0–1.3) 1
CDKN1B Cyclin-dependent kinase inhibitor 1B (p27, Kip1) 209112_at 1.3 (1.1–1.5) 0.0132
CDKN1A Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 202284_s_at 0.68 (0.59–0.79) 1.21E-05
TK1 Thymidine kinase 1, soluble 202338_at 1.2 (1.0–1.4) 0.506
TK2 Thymidine kinase 2, mitochondrial 204227_s_at 0.53 (0.45–0.62) 7.26E-15a
204276_at 0.67 (0.58–0.78) 4.18E-06
204277_s_at 0.81 (0.70–0.94) 0.1496
TOP2A Topoisomerase (DNA) II alpha 170 kDa 201291_s_at 2.3 (2.0–2.7) \1e-16
201292_at 1.8 (1.6–2.1) 2.05E-13a
TOP2B Topoisomerase (DNA) II beta 180 kDa 211987_at 1.7 (1.5–2.0) 4.4E-11
The patients were divided into two groups as having higher or lower expression as compared to the median. Bonferroni multiple testing
correction was applied when generating the P value
RFS relapse free survival, HR hazard ratio
a See Kaplan–Meier plots on Fig. 3
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patients can be assessed by gene expression, and this option
increases the number of patients available for ER-status
dependent classification from 1,231 to 1,809.
Another important clinical question is the use of pro-
liferation-genes to predict prognosis in breast cancer
patients. A previous analysis of 32 papers could not allow
the inclusion of these markers on the list of ASCO-
approved standard prognostic and predictive factors due to
methodological problems [10]. In order to clarify these
contradictory results, we computed Kaplan–Meier plots for
the markers (MKI67, CCND1, CCND2, CCND3, CCNE1,
CCNE2, CDKN1B, CDKN1A, TK1, TK2, TOP2A, and
TOP2B) to assess their effect on prognosis. We can confirm
the prognostic value of MKI67, CCND2, CCND3, CCNE2,
and CDKN1A, as well as TK2. Both TOP2A and TOP2B
had a very high predictive power. However, the results of
CCND1, CCNE1, CDKN1B, and TK1 were (although par-
tially significant) not convincing. Therefore, we suggest the
use of above prognostic genes as measured using
microarrays.
We must note a limitation of our approach: the use of
the median (or upper/lower quartile) sample for dividing
the samples into high- and low-expression groups. In
principle, a cutoff-free correlation analysis of gene
expression and survival data is possible using Cox pro-
portional hazard models. In this frame work, significance
and hazard ratio could be assessed, but no survival curves
for a good and a poor prognosis group could be drawn. The
advantage of the use of the median for splitting is the
negligible effect of outliers, which—due to the high
dynamic range of the microarrays—could seriously skew
the results when using the mean. Moreover, median
enables to have high- and low-expression groups of virtu-
ally the same size which enables the drawing of robust
Kaplan–Meier plot. The determination of an exact cutoff
value for each transcript could improve the results. How-
ever, in this case the expression should be confirmed by
independent methods like RT–PCR or immunohistochem-
istry to achieve a reliable correlation. Such a fine-tuning—
as it has been done for the ESR1 gene in ovarian cancer
[20]—must be performed for each gene individually and is
therefore not in the scope of present study.
Finally, we added a visual enhancement to the service to
help to select the probe sets with the best quality. The
individual probes on the probe selection drop-down menu
have background color, which represents the estimated
quality of the probe set: green = excellent (average
expression of the probe set in the 1,809 patients is over
500), red = not reliable (average expression \ 100 and
maximal expression \ 500), yellow = intermediate (all
other probes).
In summary, we developed a web service which is
capable evaluating the prognostic utility of 22,277 genes in
1,809 breast cancer patients and specifically used this tool
to evaluate the effect of the proliferation-related genes in
breast cancer prognosis. The integrative genomic analysis
Fig. 3 The good prognostic effect of the over expression TK2
(a 204227_s_at) and the lower expression of TOP2A (b 201292_at)
are highly significant. The expression of Cyclin D1 is not correlated to
prognosis at all (c 208712_at)
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is still evolving; thus future integration of additional forms
of data such as sequence, location, or copy number varia-
tions might potentially add vital additional information
which will enable us to deliver higher accuracy in prog-
nosis prediction.
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